These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26629687)

  • 1. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
    Schneider JS; Seyfried TN; Choi HS; Kidd SK
    PLoS One; 2015; 10(12):e0143351. PubMed ID: 26629687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial V. cholerae sialidase protects against excitotoxic neurodegeneration.
    Dhanushkodi A; McDonald MP
    PLoS One; 2011; 6(12):e29285. PubMed ID: 22195039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
    Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V
    Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
    Schneider JS; Kean A; DiStefano L
    J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse.
    Itokazu Y; Fuchigami T; Morgan JC; Yu RK
    Mol Ther; 2021 Oct; 29(10):3059-3071. PubMed ID: 34111562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation.
    Li Y; Liu W; Li L; Hölscher C
    Eur J Pharmacol; 2017 Feb; 797():162-172. PubMed ID: 27913104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism.
    Schneider JS; Bradbury KA; Anada Y; Inokuchi J; Anderson DW
    Brain Res; 2006 Jul; 1099(1):199-205. PubMed ID: 16764837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of GM1 ganglioside treatment on dopamine innervation of the striatum of MPTP-treated mice.
    Rothblat DS; Schneider JS
    Ann N Y Acad Sci; 1998 Jun; 845():274-7. PubMed ID: 9668361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
    Schneider JS; DiStefano L
    Brain Res; 1995 Mar; 674(2):260-4. PubMed ID: 7796105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
    Hadaczek P; Wu G; Sharma N; Ciesielska A; Bankiewicz K; Davidow AL; Lu ZH; Forsayeth J; Ledeen RW
    Exp Neurol; 2015 Jan; 263():177-89. PubMed ID: 25448159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
    Schneider JS
    J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
    Chen Y; Zhang Y; Li L; Hölscher C
    Eur J Pharmacol; 2015 Dec; 768():21-7. PubMed ID: 26409043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.
    Schneider JS
    PLoS One; 2018; 13(6):e0199189. PubMed ID: 29902255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.